Cargando…

Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A

BACKGROUND: When availability and/or affordability of anti-hemophilic factor concentrates are limited, optimal prophylaxis regimens in severe hemophilia A (HA) remain to be determined. In selected situations, low-dose daily prophylaxis (LDDP) may be an effective and economical option. The goal of ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizrahi, Terry, St-Louis, Jean, Young, Nancy L., Ménard, Francine, Zourikian, Nichan, Dubé, Evemie, Rivard, Georges E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101823/
https://www.ncbi.nlm.nih.gov/pubmed/27833753
http://dx.doi.org/10.1186/s12878-016-0067-3
_version_ 1782466358326329344
author Mizrahi, Terry
St-Louis, Jean
Young, Nancy L.
Ménard, Francine
Zourikian, Nichan
Dubé, Evemie
Rivard, Georges E.
author_facet Mizrahi, Terry
St-Louis, Jean
Young, Nancy L.
Ménard, Francine
Zourikian, Nichan
Dubé, Evemie
Rivard, Georges E.
author_sort Mizrahi, Terry
collection PubMed
description BACKGROUND: When availability and/or affordability of anti-hemophilic factor concentrates are limited, optimal prophylaxis regimens in severe hemophilia A (HA) remain to be determined. In selected situations, low-dose daily prophylaxis (LDDP) may be an effective and economical option. The goal of our study was to evaluate if subjects on a LDDP regimen could achieve adherence and good clinical outcome. METHODS: Seventeen subjects (age between 15.2 and 28.4) on LDDP suffering from severe/moderate HA were followed prospectively for 2 to 3 years as part of a health-related quality of life (HRQoL) study. Bleeding and treatments data were collected using electronic diaries and validated every three months. The SF-36 questionnaire was administered at the beginning of the study and then every 6 months until the end of the study. RESULTS: The subjects (mean age 22.0, median 21.9, standard deviation 4.06), were all from a single centre and on LDDP for at least 12 months as part of their routine care before entering the study. Fifteen subjects were prescribed a daily dose of 500 IU factor VIII (FVIII) and 2 subjects received 1000 IU FVIII per day, resulting into a median dose of 7.1 IU/kg/day (ranging from 4 to 13 IU/kg/day) and of 2591 IU/kg/year. Median adherence (the percentage of the prescribed daily dose received) was 84 % (mean 80 %, range 57 % to 94 %) throughout the study. Seventy-six bleeds in the 6 index joints and 51 other types of bleeds were observed throughout the study. The median annualized bleeding rate in joints (ABRjoints) was 0.7 and the median annualized bleeding rate for all bleeds (ABRall) was 1.6. The Physical Component and Mental Component Summary scores of SF-36, and the Hemophilia Joint Health Score were not significantly different over the course of the study (respective medians of 49.8, 52.4 and 16.0 at entry; vs. 52.5, 51.5 and 16.0 upon exit). CONCLUSIONS: This prospective longitudinal study in youth and young adults shows that LDDP may be associated with low ABRs, adequate adherence and HRQoL comparable to previously reported.
format Online
Article
Text
id pubmed-5101823
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51018232016-11-10 Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A Mizrahi, Terry St-Louis, Jean Young, Nancy L. Ménard, Francine Zourikian, Nichan Dubé, Evemie Rivard, Georges E. BMC Hematol Research Article BACKGROUND: When availability and/or affordability of anti-hemophilic factor concentrates are limited, optimal prophylaxis regimens in severe hemophilia A (HA) remain to be determined. In selected situations, low-dose daily prophylaxis (LDDP) may be an effective and economical option. The goal of our study was to evaluate if subjects on a LDDP regimen could achieve adherence and good clinical outcome. METHODS: Seventeen subjects (age between 15.2 and 28.4) on LDDP suffering from severe/moderate HA were followed prospectively for 2 to 3 years as part of a health-related quality of life (HRQoL) study. Bleeding and treatments data were collected using electronic diaries and validated every three months. The SF-36 questionnaire was administered at the beginning of the study and then every 6 months until the end of the study. RESULTS: The subjects (mean age 22.0, median 21.9, standard deviation 4.06), were all from a single centre and on LDDP for at least 12 months as part of their routine care before entering the study. Fifteen subjects were prescribed a daily dose of 500 IU factor VIII (FVIII) and 2 subjects received 1000 IU FVIII per day, resulting into a median dose of 7.1 IU/kg/day (ranging from 4 to 13 IU/kg/day) and of 2591 IU/kg/year. Median adherence (the percentage of the prescribed daily dose received) was 84 % (mean 80 %, range 57 % to 94 %) throughout the study. Seventy-six bleeds in the 6 index joints and 51 other types of bleeds were observed throughout the study. The median annualized bleeding rate in joints (ABRjoints) was 0.7 and the median annualized bleeding rate for all bleeds (ABRall) was 1.6. The Physical Component and Mental Component Summary scores of SF-36, and the Hemophilia Joint Health Score were not significantly different over the course of the study (respective medians of 49.8, 52.4 and 16.0 at entry; vs. 52.5, 51.5 and 16.0 upon exit). CONCLUSIONS: This prospective longitudinal study in youth and young adults shows that LDDP may be associated with low ABRs, adequate adherence and HRQoL comparable to previously reported. BioMed Central 2016-11-08 /pmc/articles/PMC5101823/ /pubmed/27833753 http://dx.doi.org/10.1186/s12878-016-0067-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mizrahi, Terry
St-Louis, Jean
Young, Nancy L.
Ménard, Francine
Zourikian, Nichan
Dubé, Evemie
Rivard, Georges E.
Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title_full Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title_fullStr Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title_full_unstemmed Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title_short Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
title_sort adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia a
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101823/
https://www.ncbi.nlm.nih.gov/pubmed/27833753
http://dx.doi.org/10.1186/s12878-016-0067-3
work_keys_str_mv AT mizrahiterry adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT stlouisjean adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT youngnancyl adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT menardfrancine adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT zourikiannichan adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT dubeevemie adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa
AT rivardgeorgese adherencetotreatmentregimenandbleedingratesinaprospectivecohortofyouthandyoungadultsonlowdosedailyprophylaxisforseverehemophiliaa